Key result
Plasma exchange and VA-ECMO enable full recovery in fulminant myocarditis complicating immune-mediated TTP.
Why the study?
Cardiovascular complications including myocardial ischemia and necrosis are a leading cause of acute mortality in thrombotic thrombocytopenic purpura, but fulminant myocarditis as a complication is not well characterized.
Case Report (n=1)
No
Fulminant myocarditis is a potential, reversible cardiovascular complication in patients with immune-mediated thrombotic thrombocytopenic purpura, for which timely multidisciplinary management and mechanical circulatory support can be lifesaving.
May support VA-ECMO plus plasma exchange in TTP with fulminant myocarditis; leaves open broader efficacy and optimal protocols.
Background: Thrombotic thrombocytopenic purpura is a life-threatening thrombotic microangiopathy characterized by systemic microvascular thrombosis. Cardiovascular complications, including myocardial ischemia and necrosis, are a leading cause of acute mortality. Case Presentation: A 54-year-old man was diagnosed with immune-mediated thrombotic thrombocytopenic purpura. On Day 2, he developed sudden cardiac arrest, requiring venoarterial extracorporeal membrane oxygenation for circulatory support. Echocardiography revealed diffuse severe hypokinesis, ventricular hypertrophy, and pericardial effusion. Myocardial biopsy performed on Day 3 showed no findings of microthrombi or necrosis. These findings suggested fulminant myocarditis rather than myocardial ischemia. The patient was successfully treated with multidisciplinary treatment including plasma exchange, achieving full recovery by Day 44. Conclusion: This case highlights fulminant myocarditis as a complication of immune-mediated thrombotic thrombocytopenic purpura. As myocarditis is potentially reversible, providing appropriate supportive therapy may contribute to an improved prognosis.
No takes yet. Share an insight, caveat, or question.
Ishikita et al. (2025) conducted a case report in Immune-mediated thrombotic thrombocytopenic purpura (iTTP) (n=1). Multidisciplinary treatment including plasma exchange, VA-ECMO, and steroids was evaluated. A 54-year-old man with immune-mediated thrombotic thrombocytopenic purpura complicated by fulminant myocarditis fully recovered by Day 44 following multidisciplinary therapy including plasma exchange and VA-ECMO.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: